CN1745768B - 一种含黄芪的药物在制备治疗阿司匹林抵抗药物中的应用 - Google Patents
一种含黄芪的药物在制备治疗阿司匹林抵抗药物中的应用 Download PDFInfo
- Publication number
- CN1745768B CN1745768B CN 200410071867 CN200410071867A CN1745768B CN 1745768 B CN1745768 B CN 1745768B CN 200410071867 CN200410071867 CN 200410071867 CN 200410071867 A CN200410071867 A CN 200410071867A CN 1745768 B CN1745768 B CN 1745768B
- Authority
- CN
- China
- Prior art keywords
- aspirin
- radix
- application
- pharmaceutical composition
- salviae miltiorrhizae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 69
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title claims abstract description 67
- 229960001138 acetylsalicylic acid Drugs 0.000 title claims abstract description 65
- 241001061264 Astragalus Species 0.000 title 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 title 1
- 235000006533 astragalus Nutrition 0.000 title 1
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 29
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 29
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- 238000002360 preparation method Methods 0.000 claims description 31
- 239000009636 Huang Qi Substances 0.000 claims description 29
- 229940079593 drug Drugs 0.000 claims description 29
- 239000006187 pill Substances 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 9
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 9
- 206010002383 Angina Pectoris Diseases 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 208000029078 coronary artery disease Diseases 0.000 claims description 7
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 239000000341 volatile oil Substances 0.000 claims description 6
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 5
- -1 reflux Substances 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000012669 liquid formulation Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241000304195 Salvia miltiorrhiza Species 0.000 claims 2
- 240000007164 Salvia officinalis Species 0.000 abstract description 2
- 229940107666 astragalus root Drugs 0.000 abstract 2
- 244000138993 panchioli Species 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 239000002023 wood Substances 0.000 abstract 1
- 208000025870 aspirin resistance Diseases 0.000 description 33
- 230000000694 effects Effects 0.000 description 25
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 15
- 239000008412 qishen yiqi Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 235000017276 Salvia Nutrition 0.000 description 8
- 239000002131 composite material Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 7
- 241001072909 Salvia Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 230000004520 agglutination Effects 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 230000000391 smoking effect Effects 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000010118 platelet activation Effects 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 206010002388 Angina unstable Diseases 0.000 description 3
- 208000007814 Unstable Angina Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 244000132619 red sage Species 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- 101150071146 COX2 gene Proteins 0.000 description 2
- 101100496968 Caenorhabditis elegans ctc-1 gene Proteins 0.000 description 2
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 206010021703 Indifference Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 101100221647 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cox-1 gene Proteins 0.000 description 2
- 101150062589 PTGS1 gene Proteins 0.000 description 2
- 101150000187 PTGS2 gene Proteins 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 2
- 208000001435 Thromboembolism Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000013172 carotid endarterectomy Methods 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 239000008899 fufang danshen Substances 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 238000013146 percutaneous coronary intervention Methods 0.000 description 2
- 230000003405 preventing effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 2
- 235000021286 stilbenes Nutrition 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical group OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 2
- 229960005080 warfarin Drugs 0.000 description 2
- 206010059245 Angiopathy Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241000237903 Hirudo Species 0.000 description 1
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102100036154 Platelet basic protein Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 229940067131 aspirin 100 mg Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000003331 prothrombotic effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 238000007560 sedimentation technique Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000006441 vascular event Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410071867 CN1745768B (zh) | 2004-09-07 | 2004-09-07 | 一种含黄芪的药物在制备治疗阿司匹林抵抗药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410071867 CN1745768B (zh) | 2004-09-07 | 2004-09-07 | 一种含黄芪的药物在制备治疗阿司匹林抵抗药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1745768A CN1745768A (zh) | 2006-03-15 |
CN1745768B true CN1745768B (zh) | 2011-03-23 |
Family
ID=36165586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410071867 Active CN1745768B (zh) | 2004-09-07 | 2004-09-07 | 一种含黄芪的药物在制备治疗阿司匹林抵抗药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1745768B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101439065B (zh) * | 2007-11-22 | 2012-03-28 | 天津天士力制药股份有限公司 | 一种含三七提取物的中药颗粒及其制备方法 |
HUE054609T2 (hu) * | 2013-07-11 | 2021-09-28 | Tasly Pharmaceutical Group Co | Elkészítési eljárás hagyományos kínai gyógyszer mikrocsepp pilulához, és a hagyományos kínai gyógyszer mikrocsepp pilula, amely ennek az eljárásnak az alkalmazásával van elkészítve |
EP3020408B1 (en) | 2013-07-11 | 2022-01-12 | Tasly Pharmaceutical Group Co., Ltd. | Traditional chinese medicine composition, and preparation and application thereof |
USRE49050E1 (en) | 2013-07-11 | 2022-04-26 | Tasly Pharmaceutical Group Co., Ltd. | Traditional Chinese medicine composition, and preparation and application thereof |
CN104418744B (zh) | 2013-08-29 | 2017-03-01 | 天士力制药集团股份有限公司 | 一种新的丹酚酸化合物t、其制备方法和用途 |
CN113925892B (zh) * | 2020-06-29 | 2024-04-09 | 天士力医药集团股份有限公司 | 中药芪参益气制剂治疗胃出血的用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1375316A (zh) * | 2002-02-07 | 2002-10-23 | 天津天士力制药股份有限公司 | 治疗冠心病心绞痛的中药制剂及其制备方法 |
-
2004
- 2004-09-07 CN CN 200410071867 patent/CN1745768B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1375316A (zh) * | 2002-02-07 | 2002-10-23 | 天津天士力制药股份有限公司 | 治疗冠心病心绞痛的中药制剂及其制备方法 |
Non-Patent Citations (6)
Title |
---|
.阿司匹林抵抗的研究现状.中华心血管病杂志32 6.2004,32(6),553-556. |
盛 勇,罗 俊,张廷杰.阿司匹林抗血小板作用的抗药性——阿司匹林抵抗.心血管病学进展25 1.2004,25(1),39-40. |
盛 勇,罗 俊,张廷杰.阿司匹林抗血小板作用的抗药性——阿司匹林抵抗.心血管病学进展25 1.2004,25(1),39-40. * |
谭真 |
谭真;黄德嘉;.阿司匹林抵抗的研究现状.中华心血管病杂志32 6.2004,32(6),553-556. * |
黄德嘉 |
Also Published As
Publication number | Publication date |
---|---|
CN1745768A (zh) | 2006-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1745768B (zh) | 一种含黄芪的药物在制备治疗阿司匹林抵抗药物中的应用 | |
CN1714836A (zh) | 一种药物在制备治疗阿司匹林抵抗药物中的应用 | |
CN1714859A (zh) | 含有丹参的组合物在制备治疗阿司匹林抵抗药物中的应用 | |
CN1872315A (zh) | 含鸡血藤的药物在抗阿司匹林抵抗药物中的应用 | |
CN100411641C (zh) | 一种滴丸剂在制备治疗阿司匹林抵抗药物中的应用 | |
CN1872317A (zh) | 含丹参的药物在抗阿司匹林抵抗药物中的应用 | |
CN1714837A (zh) | 含有山楂的药物在制备治疗阿司匹林抵抗药物中的应用 | |
CN1872296A (zh) | 一种药物组合物在制备治疗阿司匹林抵抗药物中的应用 | |
CN1872316A (zh) | 一种含黄芪的药物在制备治疗阿司匹林抵抗药物中的应用 | |
CN100525822C (zh) | 治疗糖尿病肾病的胶囊 | |
CN1872248A (zh) | 一种含泽泻的药物在制备治疗阿司匹林抵抗药物中的应用 | |
CN1745780A (zh) | 一种组合物在抗阿司匹林抵抗药物中的应用 | |
CN1714833A (zh) | 一种药物在制备治疗阿司匹林抵抗药物中的应用 | |
CN106491958B (zh) | 治疗冠心病心绞痛的中药复方制剂及其制备方法 | |
CN1872312A (zh) | 一种含丹参的组合物在抗阿司匹林抵抗药物中的应用 | |
CN1724046A (zh) | 一种含黄精的药物在制备治疗阿司匹林抵抗药物中的应用 | |
CN1785323A (zh) | 一种药物在抗阿司匹林抵抗药物中的应用 | |
CN100381134C (zh) | 一种药物组合物在制备抗阿司匹林抵抗药物中的应用 | |
CN116747261A (zh) | 一种益气活血、养心安神的中药复方制剂及其用途 | |
CN100553650C (zh) | 一种药物组合物在制备抗阿司匹林抵抗药物中的应用 | |
CN1714822A (zh) | 含有川芎的药物在制备治疗阿司匹林抵抗药物中的应用 | |
CN1872151A (zh) | 一种药物在抗阿司匹林抵抗药物中的应用 | |
CN1723993A (zh) | 一种药物在抗阿司匹林抵抗药物中的应用 | |
CN1724047A (zh) | 含有赤芍的药物组合物在抗阿司匹林抵抗药物中的应用 | |
CN1723983A (zh) | 一种含黄芪组合物在制备治疗阿司匹林抵抗药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
CP03 | Change of name, title or address |
Address after: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
CP03 | Change of name, title or address |